Chiara Foglieni
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Chiara Foglieni has a total of 291 co-authors. Here are the top co-authors by number of shared publications:
- Daniela Belloni
Department of Oncology, San Raffaele Scientific Institute, Milan, Italy
8 shared publications Maria Lombardi
Cardiovascular Research Center, IRCCS San Raffaele Hospital, Milan, Italy
8 shared publications- Elisabetta Ferrero
Department of Oncology, San Raffaele Scientific Institute, Milan, Italy
7 shared publications - Maria Lombardi
Cardiovascular Research Center, IRCCS Ospedale San Raffaele, 20132 Milan, Italy
6 shared publications Ottavio Alfieri
Cardio-thoracic-vascular Department, IRCCS San Raffaele Scientific Institute, Milano, Italy
6 shared publicationsRoberto Chiesa
Division of Vascular Surgery, IRCCS Ospedale San Raffaele, Vita-Salute San Raffaele University, Milano, Italy
6 shared publications
Latest Publications
- 20 January 2026
- Published by Springer Nature in Basic Research in Cardiology
- Vol. 121 (2) , 271-284
miR-144 targets in myocardial hypertrophy and coronary microvascular dysfunction in hypertrophic cardiomyopathy: molecular research meets imaging
Aims Hypertrophic cardiomyopathy (HCM) is characterized by left ventricular hypertrophy, diastolic dysfunction and coronary microvascular dysfunction (CMD). The microRNA-144-3p (miR-144) has recently emerged as a player in HCM. This study investigates the relationship between phenotypic features of cardiac remodelling and CMD in patients with obstructive HCM and either myocardial miR-144 or target genes associated with hypertrophy and angiogenesis, namely EZH2, mTOR, VEGF-A, FGF2, CNPY-2, HIF-1α, ARNT and TP53. Methods and results Molecular data obtained by RT-qPCR, ELISA, and Western blot were integrated with echocardiographic (ECHO) and cardiac magnetic resonance (CMR) parameters of HCM patients. The miR-144 was also analysed in cardiomyocyte and arteriole areas isolated by laser capturing. The expression level of miR-144 was downregulated in HCM vs. control myocardium and correlated with CMR parameters, suggesting restrictive physiology. The miR-144 expressed by wall thickened arterioles was dramatically reduced in comparison with the cardiomyocyte areas and was correlated with negative atrial remodelling. Upregulation of miR-144 target genes including mTOR and EZH2 was observed, was prevalent in arteriole areas, consistent with hypertrophy triggering protein synthesis, and correlated with markers of diastolic dysfunction and structural remodelling by ECHO. Although VEGF-A/HIF-1α pathway genes and VEGF-A protein were upregulated, the HIF-1α and CNPY2 proteins were not. These findings suggest inefficient translation, supportive of CMD, of impaired myocardial relaxation and left atria enlargement. Conclusions These data suggest the potential role of miR-144 as molecular regulator in HCM, supporting a dual role in hypertrophy and CMD.
- 20 January 2026
- Published by Springer Nature in Basic Research in Cardiology
- Vol. 121 (2) , 271-284
miR-144 targets in myocardial hypertrophy and coronary microvascular dysfunction in hypertrophic cardiomyopathy: molecular research meets imaging
Aims Hypertrophic cardiomyopathy (HCM) is characterized by left ventricular hypertrophy, diastolic dysfunction and coronary microvascular dysfunction (CMD). The microRNA-144-3p (miR-144) has recently emerged as a player in HCM. This study investigates the relationship between phenotypic features of cardiac remodelling and CMD in patients with obstructive HCM and either myocardial miR-144 or target genes associated with hypertrophy and angiogenesis, namely EZH2, mTOR, VEGF-A, FGF2, CNPY-2, HIF-1α, ARNT and TP53. Methods and results Molecular data obtained by RT-qPCR, ELISA, and Western blot were integrated with echocardiographic (ECHO) and cardiac magnetic resonance (CMR) parameters of HCM patients. The miR-144 was also analysed in cardiomyocyte and arteriole areas isolated by laser capturing. The expression level of miR-144 was downregulated in HCM vs. control myocardium and correlated with CMR parameters, suggesting restrictive physiology. The miR-144 expressed by wall thickened arterioles was dramatically reduced in comparison with the cardiomyocyte areas and was correlated with negative atrial remodelling. Upregulation of miR-144 target genes including mTOR and EZH2 was observed, was prevalent in arteriole areas, consistent with hypertrophy triggering protein synthesis, and correlated with markers of diastolic dysfunction and structural remodelling by ECHO. Although VEGF-A/HIF-1α pathway genes and VEGF-A protein were upregulated, the HIF-1α and CNPY2 proteins were not. These findings suggest inefficient translation, supportive of CMD, of impaired myocardial relaxation and left atria enlargement. Conclusions These data suggest the potential role of miR-144 as molecular regulator in HCM, supporting a dual role in hypertrophy and CMD.
- Open Access
- 7 November 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-17
P2X7 and inflammatory fingerprinting of patients with carotid atherosclerosis and the risk of abdominal aortic aneurysm
Co-presentation of carotid plaque (CPL) and abdominal aortic aneurysm (AAA) is frequent and synergy in the development proposed. Inflammatory mediators affect this growth but their interplay in inducing single or multiple vascular damage scarcely explored. Healthy people and characterized male patients undergoing aneurysmectomy or endarterectomy with significant/not significant CPL and large AAA or no/small AAA were allocated to groups. CPL distribution along the carotid branches differed in patients without vs. with large AAA. ELISA and 15plex Luminex assays in serum and lesioned arteries revealed intergroup differences in the content of P2X7, GM-CSF, CXCL1, IL-1β, IL-10, IL-12p70, CCL 3, TNFα, and RT-qPCR in the expression of P2X7-targeting microRNA, namely miR-150. These data identified group-distinctive inflammatory fingerprints, stratifying patients. In silico analysis of fingerprints showed GO processes common/exclusive to groups, supporting mechanistic difference associated to lesion presentation. In vitro aortic endothelial cells respond to serum from patients with both AAA and CPL but not with only CPL, increasing P2X7, IL1B and CXCL1 genes and P2X7 isoforms, hinting to a relation between serum fingerprints and artery type. Fingerprinting may represent a stratifying tool for patients with CPL and AAA; P2X7, GM-CSF, IL-1β and CXCL1 emerge as potential candidates for personalized monitoring and therapy.
- 7 November 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-17
Open AccessP2X7 and inflammatory fingerprinting of patients with carotid atherosclerosis and the risk of abdominal aortic aneurysm
Co-presentation of carotid plaque (CPL) and abdominal aortic aneurysm (AAA) is frequent and synergy in the development proposed. Inflammatory mediators affect this growth but their interplay in inducing single or multiple vascular damage scarcely explored. Healthy people and characterized male patients undergoing aneurysmectomy or endarterectomy with significant/not significant CPL and large AAA or no/small AAA were allocated to groups. CPL distribution along the carotid branches differed in patients without vs. with large AAA. ELISA and 15plex Luminex assays in serum and lesioned arteries revealed intergroup differences in the content of P2X7, GM-CSF, CXCL1, IL-1β, IL-10, IL-12p70, CCL 3, TNFα, and RT-qPCR in the expression of P2X7-targeting microRNA, namely miR-150. These data identified group-distinctive inflammatory fingerprints, stratifying patients. In silico analysis of fingerprints showed GO processes common/exclusive to groups, supporting mechanistic difference associated to lesion presentation. In vitro aortic endothelial cells respond to serum from patients with both AAA and CPL but not with only CPL, increasing P2X7, IL1B and CXCL1 genes and P2X7 isoforms, hinting to a relation between serum fingerprints and artery type. Fingerprinting may represent a stratifying tool for patients with CPL and AAA; P2X7, GM-CSF, IL-1β and CXCL1 emerge as potential candidates for personalized monitoring and therapy.
- Open Access
Ladarixin Potential over the Effects of IL-8 and of Serum from Patients with Abdominal Aortic Aneurysm on Human Aortic Cells
Early cellular alterations in abdominal aortic aneurysm (AAA) are scarcely investigated. Aortic remodeling inflammation-related suggested the CXCR2/CXCL1/IL-8 axis as a therapeutic target. This study investigates CXCR1/CXCR2 antagonism in primary human aortic endothelial (HAOEC) and smooth muscle cells (HAOSMC) conditioned with IL-8 or serum from patients with AAA (sPT). Ladarixin (10 μM Lad or 25 μM) served as an inhibitor. Readouts included RT-qPCR for CXCL1, CXCL8, CXCR2, MMP9, NFKB1, and VEGF-A; zymography for MMP9 activity confocal microscopy for F-actin and mitochondria; NADPH/NADH diaphorase histochemistry for redox activity; and ATP assay. In HAOEC, IL-8 downregulated CXCR2, increased MMP9 activity, and induced cytoskeletal and mitochondria disorganization without altering NADH/NADPH diaphorases but increasing ATP release. At concentration of 10 μM Lad rescued cell organization and gene expression. sPT upregulated CXCL8, CXCR2, and MMP9, decreased NADH/NADPH diaphorases, and altered cytoskeleton and mitochondria organization in HAOEC. At concentration of 10 μM Lad (partially) and 25 μM Lad reverted gene upregulation and mitochondria distribution; both doses increased diaphorase and released ATP. HAOSMC were scantily susceptible to IL-8 and weakly responsive to sPT, slightly upregulating CXCR2 and VEGF-A but increasing proMMP9 gelatinolysis. Ladarixin recovered proMMP9 activity and modulated CXCL1. AAA-like vascular cell alterations involve multiple inflammatory factors and are modulable by inhibition of IL-8 receptors. The results underline careful dose calibration.
Open AccessLadarixin Potential over the Effects of IL-8 and of Serum from Patients with Abdominal Aortic Aneurysm on Human Aortic Cells
Early cellular alterations in abdominal aortic aneurysm (AAA) are scarcely investigated. Aortic remodeling inflammation-related suggested the CXCR2/CXCL1/IL-8 axis as a therapeutic target. This study investigates CXCR1/CXCR2 antagonism in primary human aortic endothelial (HAOEC) and smooth muscle cells (HAOSMC) conditioned with IL-8 or serum from patients with AAA (sPT). Ladarixin (10 μM Lad or 25 μM) served as an inhibitor. Readouts included RT-qPCR for CXCL1, CXCL8, CXCR2, MMP9, NFKB1, and VEGF-A; zymography for MMP9 activity confocal microscopy for F-actin and mitochondria; NADPH/NADH diaphorase histochemistry for redox activity; and ATP assay. In HAOEC, IL-8 downregulated CXCR2, increased MMP9 activity, and induced cytoskeletal and mitochondria disorganization without altering NADH/NADPH diaphorases but increasing ATP release. At concentration of 10 μM Lad rescued cell organization and gene expression. sPT upregulated CXCL8, CXCR2, and MMP9, decreased NADH/NADPH diaphorases, and altered cytoskeleton and mitochondria organization in HAOEC. At concentration of 10 μM Lad (partially) and 25 μM Lad reverted gene upregulation and mitochondria distribution; both doses increased diaphorase and released ATP. HAOSMC were scantily susceptible to IL-8 and weakly responsive to sPT, slightly upregulating CXCR2 and VEGF-A but increasing proMMP9 gelatinolysis. Ladarixin recovered proMMP9 activity and modulated CXCL1. AAA-like vascular cell alterations involve multiple inflammatory factors and are modulable by inhibition of IL-8 receptors. The results underline careful dose calibration.
- Open Access
- 3 October 2025
- Published by MDPI AG in Biomolecules
- Vol. 15 (10) , 1411
Anticoagulation Therapies and microRNAs in Heart Failure
Heart Failure (HF) remains a major cause of mortality despite the advances in pharmacological treatment. Anticoagulation therapies, including Clopidogrel, Aspirin, Warfarin, and novel oral anticoagulants (NOACs) such as Apixaban, Rivaroxaban, Edoxaban, and Dabigatran, are frequently administered to HF patients to prevent thromboembolism and adverse, life-threatening outcomes (e.g., stroke and myocardial infarction). In these settings, drug resistance and variability in responsivity to therapeutic approaches are challenging issues. Recent studies suggest that non-coding RNAs, particularly microRNAs (miRs) may play a modulatory role in HF therapy context, affecting drug efficacy. Specific miRs have been associated with resistance to Clopidogrel (e.g., miR-223 and miR-26a), Aspirin (e.g., miR-19b-1-5p and miR-92a) and Warfarin (e.g., miR-133 and miR-137). Moreover, Digoxin, a cardiac glycoside acting also over bleeding risk, upregulates miR-132, which is involved in HF-associated cardiac alteration and hypertrophy. Evidence linking miR expression to NOAC pharmacodynamics, cardiac remodeling and regulation of the coagulation is growing. These findings highlight the need of deeply harnessing the potential of miRs as predictive biomarkers or therapeutic targets in HF. Improving the knowledge on the relationship between miR and anticoagulant drugs in HF patients will contribute to personalization of the anticoagulant therapies, aimed at enhancing patient responsivity and minimizing adverse effects, ultimately improving patient life quality.
- 3 October 2025
- Published by MDPI AG in Biomolecules
- Vol. 15 (10) , 1411
Open AccessAnticoagulation Therapies and microRNAs in Heart Failure
Heart Failure (HF) remains a major cause of mortality despite the advances in pharmacological treatment. Anticoagulation therapies, including Clopidogrel, Aspirin, Warfarin, and novel oral anticoagulants (NOACs) such as Apixaban, Rivaroxaban, Edoxaban, and Dabigatran, are frequently administered to HF patients to prevent thromboembolism and adverse, life-threatening outcomes (e.g., stroke and myocardial infarction). In these settings, drug resistance and variability in responsivity to therapeutic approaches are challenging issues. Recent studies suggest that non-coding RNAs, particularly microRNAs (miRs) may play a modulatory role in HF therapy context, affecting drug efficacy. Specific miRs have been associated with resistance to Clopidogrel (e.g., miR-223 and miR-26a), Aspirin (e.g., miR-19b-1-5p and miR-92a) and Warfarin (e.g., miR-133 and miR-137). Moreover, Digoxin, a cardiac glycoside acting also over bleeding risk, upregulates miR-132, which is involved in HF-associated cardiac alteration and hypertrophy. Evidence linking miR expression to NOAC pharmacodynamics, cardiac remodeling and regulation of the coagulation is growing. These findings highlight the need of deeply harnessing the potential of miRs as predictive biomarkers or therapeutic targets in HF. Improving the knowledge on the relationship between miR and anticoagulant drugs in HF patients will contribute to personalization of the anticoagulant therapies, aimed at enhancing patient responsivity and minimizing adverse effects, ultimately improving patient life quality.
- 11 July 2025
- Published by Springer Nature in Journal of Cardiovascular Translational Research
- Vol. 18 (5) , 1032-1041
Platelet microRNA Expression Can Predict Bleeding in HeartMate3 Patients Treated With or Without Aspirin
We tested whether platelet microRNAs (miRs) expression can predict bleeding in patients supported with the HeartMate3 (HM3) left ventricular assist device (LVAD). The levels of expression of platelet miR-126, miR-233, miR-151a, and miR-454 were prospectively measured in 12 consecutive patients pre-implant and during long-term follow-up and compared based on aspirin (ASA) or ASA-free therapy at discharge and bleeding events over the course of HM3 support. Median time of follow-up was 760 (574–844) days. Seven (58%) patients were discharged on ASA and 5 (42%) without ASA. Three (25%) patients experienced 10 bleeding episodes: one never received ASA, and two suffered from bleeding recurrency long after permanent ASA discontinuation. ASA had minimal influence on platelet miRs expression. The expression levels of platelet miR-454 were lower in bleeders vs. non-bleeders, both pre-implant and post-implant. This study suggests the existence of a patient-specific pro-hemorrhagic phenotype associated with a distinctive expression profile of platelet miR-454. Clinical Trial Registration: https://clinicaltrials.gov/ct2/show/NCT03255928. ClinicalTrials.gov Identifier: NCT03255928. Graphical Abstract
- 11 July 2025
- Published by Springer Nature in Journal of Cardiovascular Translational Research
- Vol. 18 (5) , 1032-1041
Platelet microRNA Expression Can Predict Bleeding in HeartMate3 Patients Treated With or Without Aspirin
We tested whether platelet microRNAs (miRs) expression can predict bleeding in patients supported with the HeartMate3 (HM3) left ventricular assist device (LVAD). The levels of expression of platelet miR-126, miR-233, miR-151a, and miR-454 were prospectively measured in 12 consecutive patients pre-implant and during long-term follow-up and compared based on aspirin (ASA) or ASA-free therapy at discharge and bleeding events over the course of HM3 support. Median time of follow-up was 760 (574–844) days. Seven (58%) patients were discharged on ASA and 5 (42%) without ASA. Three (25%) patients experienced 10 bleeding episodes: one never received ASA, and two suffered from bleeding recurrency long after permanent ASA discontinuation. ASA had minimal influence on platelet miRs expression. The expression levels of platelet miR-454 were lower in bleeders vs. non-bleeders, both pre-implant and post-implant. This study suggests the existence of a patient-specific pro-hemorrhagic phenotype associated with a distinctive expression profile of platelet miR-454. Clinical Trial Registration: https://clinicaltrials.gov/ct2/show/NCT03255928. ClinicalTrials.gov Identifier: NCT03255928. Graphical Abstract
- 25 September 2024
- Published by Elsevier in International Journal of Cardiology
- Vol. 418, 132600
Circular RNAs interplay with Coronary Microvascular Dysfunction: A prognostic key for patients with coronary artery disease?
- 25 September 2024
- Published by Elsevier in International Journal of Cardiology
- Vol. 418, 132600
Circular RNAs interplay with Coronary Microvascular Dysfunction: A prognostic key for patients with coronary artery disease?
- 5 September 2024
- Published by Oxford University Press (OUP) in Cardiovascular Research
- Vol. 120 (15) , 1832-1834
Modulation of MMP9 and CXCR2/CXCL1/IL-8 axis in human abdominal aortic aneurysm tissues by ladarixin
Abdominal aortic aneurysm (AAA) is a multifactorial, mainly silent disease leading to aortic dilatation through alteration of all the artery layers, extracellular matrix (ECM) hyperdegradation and inflammation, prevalent in men older than 60 years.1 AAA ruptures, accounting for about 200 000 deaths/year worldwide, are associated to the aortic diameter. Surgical repair remains the elective treatment for large AAA.2 Following discrepant results from clinical trials on AAA pharmacotherapy,3 non-surgical management of AAA and identification of a medical treatment slowing AAA growth are unmet medical needs. The MMP9 upregulation is a key event during AAA growth2 and modulation of ECM degradation an emerging target (e.g. MAAAGI trial, NCT0422405). The CXCR1/CXCR2 antagonism by non-competitive allosteric inhibitor ladarixin (Dompé Farmaceutici S.p.A., Milano, Italy) reduced MMP9 and leucocyte infiltration in a murine AAA model.4 Nevertheless, the clinical relevance of ladarixin (approved for the treatment of type I diabetes mellitus, EMEA-002642-PIP01-19-M03) in cardiovascular diseases and of CXCR2 as therapeutic target in human AAA remain both unaddressed. CXCR2 interacts with multiple cytokines including CXCL1 and its homologue CXCL8 (synonym: IL-8), which play chemotactic and angiogenic roles, e.g. immune cell recruitment at site of inflammation.5,6 Circulating IL-8 is related to the diameter of small AAA, and human AAA hyper-express IL-8.4 MMP9 release from in vitro–activated neutrophils is induced by IL-8 and CXCL1 and reduced by pharmacological blockade of CXCR2.5 In turn, MMP9 proteolytically activates IL-8 but inactivates CXCL1.5
- 5 September 2024
- Published by Oxford University Press (OUP) in Cardiovascular Research
- Vol. 120 (15) , 1832-1834
Modulation of MMP9 and CXCR2/CXCL1/IL-8 axis in human abdominal aortic aneurysm tissues by ladarixin
Abdominal aortic aneurysm (AAA) is a multifactorial, mainly silent disease leading to aortic dilatation through alteration of all the artery layers, extracellular matrix (ECM) hyperdegradation and inflammation, prevalent in men older than 60 years.1 AAA ruptures, accounting for about 200 000 deaths/year worldwide, are associated to the aortic diameter. Surgical repair remains the elective treatment for large AAA.2 Following discrepant results from clinical trials on AAA pharmacotherapy,3 non-surgical management of AAA and identification of a medical treatment slowing AAA growth are unmet medical needs. The MMP9 upregulation is a key event during AAA growth2 and modulation of ECM degradation an emerging target (e.g. MAAAGI trial, NCT0422405). The CXCR1/CXCR2 antagonism by non-competitive allosteric inhibitor ladarixin (Dompé Farmaceutici S.p.A., Milano, Italy) reduced MMP9 and leucocyte infiltration in a murine AAA model.4 Nevertheless, the clinical relevance of ladarixin (approved for the treatment of type I diabetes mellitus, EMEA-002642-PIP01-19-M03) in cardiovascular diseases and of CXCR2 as therapeutic target in human AAA remain both unaddressed. CXCR2 interacts with multiple cytokines including CXCL1 and its homologue CXCL8 (synonym: IL-8), which play chemotactic and angiogenic roles, e.g. immune cell recruitment at site of inflammation.5,6 Circulating IL-8 is related to the diameter of small AAA, and human AAA hyper-express IL-8.4 MMP9 release from in vitro–activated neutrophils is induced by IL-8 and CXCL1 and reduced by pharmacological blockade of CXCR2.5 In turn, MMP9 proteolytically activates IL-8 but inactivates CXCL1.5
- Open Access
- 15 June 2023
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 10, 1178556
Left ventricular assist devices promote changes in the expression levels of platelet microRNAs
Introduction: MicroRNAs (miRs) emerged as promising diagnostic and therapeutic biomarkers in cardiovascular diseases. The potential clinical utility of platelet miRs in the setting of left ventricular assist device (LVAD) support is unexplored.Methods: We prospectively measured the expression levels of 12 platelet miRs involved in platelet activation, coagulation, and cardiovascular diseases in LVAD patients by quantitative real-time polymerase chain reaction. Data were longitudinally measured before LVAD implant and after 1, 6, and 12 months of LVAD support, and compared with those measured in healthy volunteers (controls). In silico analysis was also performed to identify pathways targeted by differentially expressed miRs.Results: Data from 15 consecutive patients and 5 controls were analyzed. Pre-implant expression levels of platelet miR-126, miR-374b, miR-223, and miR-320a were significantly different in patients vs. controls. The expression levels of platelet miR-25, miR-144, miR-320, and miR-451a changed significantly over the course of LVAD support; in silico analysis revealed that these miRs are implicated in both cardiac- and coagulation-associated pathways. Furthermore, the patients who suffered from bleeding (n = 5, 33%) had significantly higher pre-implant expression levels of platelet miR-151a and miR-454 with respect to the patients who did not. The same miRs were also differentially expressed in bleeders following LVAD implantation early before the clinical manifestation of the events.Discussion: This study provides a proof-of-concept evidence of significant modulation of platelet miRs expression driven by LVADs. The possible existence of a platelet miRs signature predictive of the development of bleeding events warrants further validation studies.
- 15 June 2023
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 10, 1178556
Open AccessLeft ventricular assist devices promote changes in the expression levels of platelet microRNAs
Introduction: MicroRNAs (miRs) emerged as promising diagnostic and therapeutic biomarkers in cardiovascular diseases. The potential clinical utility of platelet miRs in the setting of left ventricular assist device (LVAD) support is unexplored.Methods: We prospectively measured the expression levels of 12 platelet miRs involved in platelet activation, coagulation, and cardiovascular diseases in LVAD patients by quantitative real-time polymerase chain reaction. Data were longitudinally measured before LVAD implant and after 1, 6, and 12 months of LVAD support, and compared with those measured in healthy volunteers (controls). In silico analysis was also performed to identify pathways targeted by differentially expressed miRs.Results: Data from 15 consecutive patients and 5 controls were analyzed. Pre-implant expression levels of platelet miR-126, miR-374b, miR-223, and miR-320a were significantly different in patients vs. controls. The expression levels of platelet miR-25, miR-144, miR-320, and miR-451a changed significantly over the course of LVAD support; in silico analysis revealed that these miRs are implicated in both cardiac- and coagulation-associated pathways. Furthermore, the patients who suffered from bleeding (n = 5, 33%) had significantly higher pre-implant expression levels of platelet miR-151a and miR-454 with respect to the patients who did not. The same miRs were also differentially expressed in bleeders following LVAD implantation early before the clinical manifestation of the events.Discussion: This study provides a proof-of-concept evidence of significant modulation of platelet miRs expression driven by LVADs. The possible existence of a platelet miRs signature predictive of the development of bleeding events warrants further validation studies.
- Open Access
- 3 September 2022
- Published by MDPI AG in Biomedicines
- Vol. 10 (9) , 2180
Myosins and MyomiR Network in Patients with Obstructive Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy (HCM) is the most common genetic cardiomyopathy. The molecular mechanisms determining HCM phenotypes are incompletely understood. Myocardial biopsies were obtained from a group of patients with obstructive HCM (n = 23) selected for surgical myectomy and from 9 unused donor hearts (controls). A subset of tissue-abundant myectomy samples from HCM (n = 10) and controls (n = 6) was submitted to laser-capture microdissection to isolate cardiomyocytes. We investigated the relationship among clinical phenotype, cardiac myosin proteins (MyHC6, MyHC7, and MyHC7b) measured by optimized label-free mass spectrometry, the relative genes (MYH7, MYH7B and MYLC2), and the MyomiR network (myosin-encoded microRNA (miRs) and long-noncoding RNAs (Mhrt)) measured using RNA sequencing and RT-qPCR. MyHC6 was lower in HCM vs. controls, whilst MyHC7, MyHC7b, and MyLC2 were comparable. MYH7, MYH7B, and MYLC2 were higher in HCM whilst MYH6, miR-208a, miR-208b, miR-499 were comparable in HCM and controls. These results are compatible with defective transcription by active genes in HCM. Mhrt and two miR-499-target genes, SOX6 and PTBP3, were upregulated in HCM. The presence of HCM-associated mutations correlated with PTBP3 in myectomies and with SOX6 in cardiomyocytes. Additionally, iPSC-derived cardiomyocytes, transiently transfected with either miR-208a or miR-499, demonstrated a time-dependent relationship between MyomiRs and myosin genes. The transfection end-stage pattern was at least in part similar to findings in HCM myectomies. These data support uncoupling between myosin protein/genes and a modulatory role for the myosin/MyomiR network in the HCM myocardium, possibly contributing to phenotypic diversity and providing putative therapeutic targets.
- 3 September 2022
- Published by MDPI AG in Biomedicines
- Vol. 10 (9) , 2180
Open AccessMyosins and MyomiR Network in Patients with Obstructive Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy (HCM) is the most common genetic cardiomyopathy. The molecular mechanisms determining HCM phenotypes are incompletely understood. Myocardial biopsies were obtained from a group of patients with obstructive HCM (n = 23) selected for surgical myectomy and from 9 unused donor hearts (controls). A subset of tissue-abundant myectomy samples from HCM (n = 10) and controls (n = 6) was submitted to laser-capture microdissection to isolate cardiomyocytes. We investigated the relationship among clinical phenotype, cardiac myosin proteins (MyHC6, MyHC7, and MyHC7b) measured by optimized label-free mass spectrometry, the relative genes (MYH7, MYH7B and MYLC2), and the MyomiR network (myosin-encoded microRNA (miRs) and long-noncoding RNAs (Mhrt)) measured using RNA sequencing and RT-qPCR. MyHC6 was lower in HCM vs. controls, whilst MyHC7, MyHC7b, and MyLC2 were comparable. MYH7, MYH7B, and MYLC2 were higher in HCM whilst MYH6, miR-208a, miR-208b, miR-499 were comparable in HCM and controls. These results are compatible with defective transcription by active genes in HCM. Mhrt and two miR-499-target genes, SOX6 and PTBP3, were upregulated in HCM. The presence of HCM-associated mutations correlated with PTBP3 in myectomies and with SOX6 in cardiomyocytes. Additionally, iPSC-derived cardiomyocytes, transiently transfected with either miR-208a or miR-499, demonstrated a time-dependent relationship between MyomiRs and myosin genes. The transfection end-stage pattern was at least in part similar to findings in HCM myectomies. These data support uncoupling between myosin protein/genes and a modulatory role for the myosin/MyomiR network in the HCM myocardium, possibly contributing to phenotypic diversity and providing putative therapeutic targets.
- Open Access
Identification of CX3CR1+ mononuclear phagocyte subsets involved in HIV-1 and SIV colorectal transmission